Anteris Technologies Global Corp.

Anteris Technologies Global Corp. is a structural heart company dedicated to advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its principal executive offices are located in Eagan, Minnesota, USA, with additional operations in Australia and Switzerland.

The company's primary product is the DurAVR Transcatheter Heart Valve (THV) System, designed to treat Aortic Stenosis, a life-threatening condition caused by the narrowing of the aortic valve. The DurAVR THV is a balloon-expandable, biomimetic valve that utilizes Anteris' proprietary ADAPT anti-calcification tissue technology and the ComASUR Delivery System, aiming to mimic the performance of a healthy human aortic valve and restore normal aortic blood flow. Anteris Technologies operates in key markets including the United States, Germany, Australia, Switzerland, and Sweden.

In recent developments, Anteris Technologies Global Corp. secured a strategic investment of up to $90 million from Medtronic in January 2026, as part of a larger $320 million capital raise, to support the global pivotal PARADIGM Trial for its DurAVR THV. The FDA has approved this trial. Wells Fargo initiated coverage on the company with an Overweight rating in March 2026. Wayne Paterson serves as the Vice Chairman and CEO. The company also recently terminated a development agreement with v2vmedtech in April 2026.